Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
Recruitment status was: Active, not recruiting
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.
|Cardiac Toxicity Chemotherapeutic Agent Toxicity Lymphoma||Drug: doxorubicin hydrochloride Procedure: contrast-enhanced magnetic resonance imaging|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Primary Purpose: Diagnostic
|Official Title:||Cardiac MRI for Assessment of Cardiac Structure and Function Following Doxorubicin Based Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma|
- Change in myocardial function and structure [ Time Frame: cMRI will be done prior to induction of doxorubicin based chemotherapy and at three months after completion of the doxorubicin based chemotherapy regimen. ]
|Study Start Date:||November 2007|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Drug: doxorubicin hydrochloride
- To determine whether early myocardial structural and functional changes can be detected using cardiac MRI in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin hydrochloride-based chemotherapy.
OUTLINE: Patients undergo cardiac MRI with gadolinium contrast prior to initiation of doxorubicin hydrochloride-based chemotherapy and 3 months after completion of six courses of chemotherapy for non-Hodgkin lymphoma and twelve courses of chemotherapy for Hodgkin lymphoma.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00577798
|United States, Nebraska|
|UNMC Eppley Cancer Center at the University of Nebraska Medical Center|
|Omaha, Nebraska, United States, 68198-6805|
|Principal Investigator:||Thomas R. Porter, M.D.||University of Nebraska|